BCRX Message Board Post 10867956 | BioCryst Pharmaceuticals...
home / stock / bcrx / bcrx message board
(investorshangout)
Posted on: Aug/31/2022 14:10:56
Source: investorshangout
https://investorshangout.com/post/view?id=6463495
whytestocks: $BCRX News Article - FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, BCX9250, for
News, Short Squeeze, Breakout and More Instantly...
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
Market:
0.91% G/L:
$7.98 Last:
4,927,265 Volume:
$7.62 Open:
$7.98 Close:
BioCryst Pharmaceuticals Inc. Website:
-
2025-02-24 18:15:51 ET Investors clearly weren't in a forgiving mood on Monday when it came to BioCryst Pharmaceuticals (NASDAQ: BCRX) stock. After the commercial-stage biotech published its fourth-quarter and full-year 2024 results, they traded its shares down by an even 10% on the...
-
2025-02-24 16:30:21 ET Image source: The Motley Fool. BioCryst Pharmaceuticals (NASDAQ: BCRX) Q4 2024 Earnings Call Feb 24, 2025 , 8:30 a.m. ET Operator Continue reading
-
—ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)— —FY 2025 ORLADEYO net revenue guidance increased to between $535-$550 million (previously $515-$535 million)— —...